Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real world evidence (RWE) study of ZYTIGA (Abiraterone Acetate) plus prednisone for the treatment of asymptomatic and mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Trial Profile

Real world evidence (RWE) study of ZYTIGA (Abiraterone Acetate) plus prednisone for the treatment of asymptomatic and mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2017 New trial record
    • 17 Feb 2017 According to a Janssen media release, results from this study were presented at American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
    • 17 Feb 2017 Results published in the Janssen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top